PDB Short entry for 1KA7 HEADER IMMUNE SYSTEM 31-OCT-01 1KA7 TITLE SAP/SH2D1A BOUND TO PEPTIDE N-Y-C COMPND MOL_ID: 1; COMPND 2 MOLECULE: SH2 DOMAIN PROTEIN 1A; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: SLAM-ASSOCIATED PROTEIN; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: PEPTIDE N-Y-C; COMPND 8 CHAIN: B; COMPND 9 FRAGMENT: CYTOPLASMIC REGION (RESIDUES 275-286); COMPND 10 SYNONYM: SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE; COMPND 11 ENGINEERED: YES; COMPND 12 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET3A; SOURCE 10 MOL_ID: 2; SOURCE 11 SYNTHETIC: YES; SOURCE 12 OTHER_DETAILS: THIS PEPTIDE WAS CHEMICALLY SYNTHESIZED (SOLID PHASE SOURCE 13 SYNTHESIS). THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SOURCE 14 SAPIENS (HUMAN). KEYWDS SH2 DOMAIN, PROTEIN-PEPTIDE COMPLEX, IMMUNE SYSTEM EXPDTA SOLUTION NMR MDLTYP MINIMIZED AVERAGE AUTHOR P.M.HWANG,C.LI,M.MORRA,J.LILLYWHITE,F.GERTLER,C.TERHORST,L.E.KAY, AUTHOR 2 T.PAWSON,J.FORMAN-KAY,S.-C.LI REVDAT 5 27-OCT-21 1KA7 1 REMARK SEQADV REVDAT 4 24-FEB-09 1KA7 1 VERSN REVDAT 3 30-SEP-03 1KA7 1 JRNL DBREF REVDAT 2 28-AUG-02 1KA7 1 JRNL REVDAT 1 07-NOV-01 1KA7 0 JRNL AUTH P.M.HWANG,C.LI,M.MORRA,J.LILLYWHITE,D.R.MUHANDIRAM, JRNL AUTH 2 F.GERTLER,C.TERHORST,L.E.KAY,T.PAWSON,J.D.FORMAN-KAY,S.C.LI JRNL TITL A "THREE-PRONGED" BINDING MECHANISM FOR THE SAP/SH2D1A SH2 JRNL TITL 2 DOMAIN: STRUCTURAL BASIS AND RELEVANCE TO THE XLP SYNDROME. JRNL REF EMBO J. V. 21 314 2002 JRNL REFN ISSN 0261-4189 JRNL PMID 11823424 JRNL DOI 10.1093/EMBOJ/21.3.314 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : ARIA 1.0, ARIA 1.0 REMARK 3 AUTHORS : NILGES (ARIA), NILGES (ARIA) REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1KA7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 02-NOV-01. REMARK 100 THE DEPOSITION ID IS D_1000014753. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 303 REMARK 210 PH : 6.0 REMARK 210 IONIC STRENGTH : 120 MM REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 1 MM SAP U-15N, 13C; 1MM N-PY; REMARK 210 20 MM PHOSPHATE BUFFER, 100MM REMARK 210 NACL REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 3D_15N,13C-SEPARATED NOESY; 3D REMARK 210 HNHB; 3D_HN(CO)HB REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ REMARK 210 SPECTROMETER MODEL : INOVA REMARK 210 SPECTROMETER MANUFACTURER : VARIAN REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NMRPIPE 1.8, NMRVIEW 3.0 REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : NULL REMARK 210 CONFORMERS, NUMBER SUBMITTED : 1 REMARK 210 CONFORMERS, SELECTION CRITERIA : NULL REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : NULL REMARK 210 REMARK 210 REMARK: THE STRUCTURE WAS DETERMINED USING TRIPLE-RESONANCE NMR REMARK 210 SPECTROSCOPY. REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 465 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 RES C SSSEQI REMARK 465 ALA A 108 REMARK 465 ARG A 109 REMARK 465 SER A 110 REMARK 465 THR A 111 REMARK 465 GLN A 112 REMARK 465 GLY A 113 REMARK 465 THR A 114 REMARK 465 THR A 115 REMARK 465 GLY A 116 REMARK 465 ILE A 117 REMARK 465 ARG A 118 REMARK 465 GLU A 119 REMARK 465 ASP A 120 REMARK 465 PRO A 121 REMARK 465 ASP A 122 REMARK 465 VAL A 123 REMARK 465 CYS A 124 REMARK 465 LEU A 125 REMARK 465 LYS A 126 REMARK 465 ALA A 127 REMARK 465 PRO A 128 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 2 70.77 56.25 REMARK 500 SER A 36 -31.87 -131.94 REMARK 500 PRO A 70 91.67 -63.61 REMARK 500 GLN A 92 20.63 -149.00 REMARK 500 LEU A 98 133.81 -35.48 REMARK 500 GLN A 99 -47.55 -138.19 REMARK 500 LYS A 105 -72.70 -166.91 REMARK 500 SER B 277 101.38 -161.70 REMARK 500 LEU B 278 52.34 -106.81 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1KA6 RELATED DB: PDB REMARK 900 SAP/SH2D1A BOUND TO PEPTIDE N-PY DBREF 1KA7 A 1 128 UNP O60880 SH21A_HUMAN 1 128 DBREF 1KA7 B 275 286 UNP Q13291 SLAF1_HUMAN 275 286 SEQADV 1KA7 ARG B 275 UNP Q13291 LYS 275 ENGINEERED MUTATION SEQRES 1 A 128 MET ASP ALA VAL ALA VAL TYR HIS GLY LYS ILE SER ARG SEQRES 2 A 128 GLU THR GLY GLU LYS LEU LEU LEU ALA THR GLY LEU ASP SEQRES 3 A 128 GLY SER TYR LEU LEU ARG ASP SER GLU SER VAL PRO GLY SEQRES 4 A 128 VAL TYR CYS LEU CYS VAL LEU TYR HIS GLY TYR ILE TYR SEQRES 5 A 128 THR TYR ARG VAL SER GLN THR GLU THR GLY SER TRP SER SEQRES 6 A 128 ALA GLU THR ALA PRO GLY VAL HIS LYS ARG TYR PHE ARG SEQRES 7 A 128 LYS ILE LYS ASN LEU ILE SER ALA PHE GLN LYS PRO ASP SEQRES 8 A 128 GLN GLY ILE VAL ILE PRO LEU GLN TYR PRO VAL GLU LYS SEQRES 9 A 128 LYS SER SER ALA ARG SER THR GLN GLY THR THR GLY ILE SEQRES 10 A 128 ARG GLU ASP PRO ASP VAL CYS LEU LYS ALA PRO SEQRES 1 B 12 ARG LYS SER LEU THR ILE TYR ALA GLN VAL GLN LYS HELIX 1 1 SER A 12 GLY A 24 1 13 HELIX 2 2 LYS A 81 GLN A 88 1 8 SHEET 1 A 5 TRP A 64 ALA A 66 0 SHEET 2 A 5 TYR A 50 GLN A 58 -1 N SER A 57 O SER A 65 SHEET 3 A 5 TYR A 41 TYR A 47 -1 N TYR A 41 O VAL A 56 SHEET 4 A 5 SER A 28 ASP A 33 -1 N ARG A 32 O CYS A 42 SHEET 5 A 5 TYR A 7 GLY A 9 1 N GLY A 9 O ASP A 33 SHEET 1 B 5 TRP A 64 ALA A 66 0 SHEET 2 B 5 TYR A 50 GLN A 58 -1 N SER A 57 O SER A 65 SHEET 3 B 5 TYR A 41 TYR A 47 -1 N TYR A 41 O VAL A 56 SHEET 4 B 5 SER A 28 ASP A 33 -1 N ARG A 32 O CYS A 42 SHEET 5 B 5 TYR A 100 PRO A 101 1 O TYR A 100 N TYR A 29 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000